Compare KT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KT | AXSM |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 7.4B |
| IPO Year | 1999 | 2015 |
| Metric | KT | AXSM |
|---|---|---|
| Price | $19.09 | $152.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $176.00 |
| AVG Volume (30 Days) | ★ 1.7M | 464.4K |
| Earning Date | 02-12-2026 | 02-17-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.80 | N/A |
| Revenue | ★ $19,913,724,353.00 | $561,263,000.00 |
| Revenue This Year | $7.74 | $66.40 |
| Revenue Next Year | N/A | $56.13 |
| P/E Ratio | $12.94 | ★ N/A |
| Revenue Growth | 5.39 | ★ 65.83 |
| 52 Week Low | $15.49 | $75.56 |
| 52 Week High | $21.61 | $158.57 |
| Indicator | KT | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 58.25 |
| Support Level | $18.47 | $152.41 |
| Resistance Level | $19.10 | $158.56 |
| Average True Range (ATR) | 0.29 | 4.13 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 81.60 | 55.41 |
KT is South Korea's largest fixed-line telecom operator, with around 11.5 million fixed-line broadband customers and 9.5 million IPTV customers, and is the second-largest wireless operator with 28 million subscribers. Additionally, it has a number of nontelecom businesses, including real estate, payment processing, artificial intelligence, and IDC/cloud services, many of which are the focus of its growth strategy. The company was formed from the previously government-owned, monopoly telecom business and was listed in 1998. After selling its mobile business in 1994 (forming its mobile competitor, SK Telecom) KT created its own mobile operator in 1997.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.